These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10741859)

  • 21. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
    Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF
    J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Image Analysis Approach Reveals a Role for Complement Receptors 1 and 2 in Follicular Dendritic Cell Organization in Germinal Centers.
    Anania JC; Westin A; Adler J; Heyman B
    Front Immunol; 2021; 12():655753. PubMed ID: 33912182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
    Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement receptors CD21 and CD35 in humoral immunity.
    Roozendaal R; Carroll MC
    Immunol Rev; 2007 Oct; 219():157-66. PubMed ID: 17850488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
    Toapanta FR; Ross TM
    Immunol Res; 2006; 36(1-3):197-210. PubMed ID: 17337780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
    J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CR2 complement receptor.
    Cooper NR; Bradt BM; Rhim JS; Nemerow GR
    J Invest Dermatol; 1990 Jun; 94(6 Suppl):112S-117S. PubMed ID: 2161885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
    Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
    Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
    Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
    J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of complement receptor 2 calcium signaling enhancement using flow cytometry.
    Donius LR; Weis JH
    Methods Mol Biol; 2014; 1100():311-7. PubMed ID: 24218270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of complement receptor (CR) 2 and CR2-C3d complexes.
    Hannan J; Young K; Szakonyi G; Overduin MJ; Perkins SJ; Chen X; Holers VM
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):983-9. PubMed ID: 12440958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
    Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
    J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
    Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
    J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
    Barel M; Fiandino A; Lyamani F; Frade R
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
    Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
    J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
    Kulik L; Hewitt FB; Willis VC; Rodriguez R; Tomlinson S; Holers VM
    Mol Immunol; 2015 Feb; 63(2):479-88. PubMed ID: 25457881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2.
    Kacani L; Prodinger WM; Sprinzl GM; Schwendinger MG; Spruth M; Stoiber H; Döpper S; Steinhuber S; Steindl F; Dierich MP
    J Virol; 2000 Sep; 74(17):7997-8002. PubMed ID: 10933708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of a novel Cr2 gene allele by homologous recombination that abrogates production of Cr2 but is sufficient for expression of Cr1.
    Donius LR; Orlando CM; Weis JJ; Weis JH
    Immunobiology; 2014 Jan; 219(1):53-63. PubMed ID: 24012440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.
    Toapanta FR; DeAlmeida DR; Dunn MD; Ross TM
    Immunol Lett; 2010 Mar; 129(1):32-8. PubMed ID: 20064559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.